Cambridge Cognition growth in revenue of 31%

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced its unaudited interim results for the six months ended 30 June 2022.

The Company followed its strong performance in 2021 with a 31% growth in revenues to £5.9million in the first half of 2022 (H1 2021: £4.5 million). Order intake was in line with the Board’s expectations at £7.2 million, up 44% on a like-for-like basis on H1 2021 (H1 2021:£8.6 million, including £3.6 million of one-off orders) and the Company has a growing, qualified pipeline of opportunities for the second half of 2022.

The contracted order book was £18.6 million at 30 June 2022 increasing from £17.1m at 31 December 2021. The order book provides the Company with visibility over future revenues and provides a solid foundation from which the Company can continue to invest in product and commercial development to further expand the business.

Trading conditions continue to be positive, and the Company has high levels of engagement with existing and potential new clients. With continued investment in commercial activities and product development, the Company expects to achieve further year-on-year revenue growth. The cash position continued to grow to £8.6 million at 30 June 2022 and provides the business with the platform to make considered investments as opportunities arise.

Financial highlights

·         Growth in revenue of 31% to £5.9 million (H1 2021: £4.5 million)

·         Profit after tax in line with expectations at £0.02 million (H1 2021: £0.1 million)

·         Continued growth in cash balances to £8.6 million at 30 June 2022 (31 December 2021: £6.8 million)

·         Increase in like-for-like sales orders of 44% to £7.2 million (H1 2021: £8.6 million including £3.6 million of one-off orders)

·         Increase in contracted order book of £1.5 million to £18.6 million (31 December 2021: £17.1 million)

Operational highlights

·         Strengthened senior leadership team with the appointment of a Chief Financial Officer and a Chief Scientist

·         Entered a new therapeutic area for the Company, PTSD

·         Launched an Alzheimer’s validation study for the Company’s voice-based cognitive assessment solution

Commenting on the results Matthew Stork, Chief Executive Officer of Cambridge Cognition, said: “I am delighted with our continued progress over the last six months. Our contracted order book is at its highest level and, along with a healthy sales order pipeline and strong cash generation, puts us in a great position to continue to invest in strategies to grow the business further.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Cambridge Cognition Holdings

More articles like this

Cambridge Cognition Holdings

Cambridge Cognition growth strategy clearly paying off (VIDEO)

Cambridge Cognition Holdings plc (LON:COG) CEO Matthew Stork joins DirectorsTalk Interviews to discuss prelim results for the year ended 31 December 2022. In this interview Matthew talks us through the result highlights, explains how the the acquisitions of Clinpal

Cambridge Cognition Holdings

Cambridge Cognition investor webinar on 3 May 2023

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, will be announcing the Company’s preliminary financial results for the year ended 31 December 2022 on Wednesday 3 May 2023 and is pleased

Cambridge Cognition Holdings

Cambridge Cognition Holdings confirm date for year end results

Cambridge Cognition Holdings Plc (LON: COG), which develops and markets digital solutions to assess brain health, has confirmed that it will announce the Company’s preliminary financial results for the year ended 31 December 2022, on Wednesday 3 May 2023.

Cambridge Cognition Holdings

Cambridge Cognition wins two contracts worth over £2.1 million

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that it has won two sizeable contracts, together worth over £2.1 million, to provide the Company’s CANTAB® cognitive assessments and electronic

Cambridge Cognition Holdings

Cambridge Cognition 25% growth in revenues to £12.6 million

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced a trading update for the year ended 31 December 2022. Unaudited highlights for the year ended 31 December 2022 ·         Revenue ahead of

Cambridge Cognition Holdings

Cambridge Cognition acquires Winterlight Labs Inc

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced the acquisition of Winterlight Labs Inc, a leader in monitoring cognitive impairment through free-speech analysis.  The total consideration for the Acquisition is

Cambridge Cognition Holdings

Cambridge Cognition plc investor live webinar today

The interim results for the six months ended 30 June 2022 were released earlier today on 20 September 2022. The Company will conduct a live presentation and Q&A session for investors later today at 5:30 pm BST. The presentation

Cambridge Cognition Holdings

Cambridge Cognition partnering with the University of Oxford

Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that it will be collaborating with the University of Oxford by providing cognitive assessments for the Impact of Semaglutide in Amyloid

Cambridge Cognition Holdings

Cambridge Cognition signs two PTSD trial agreements

Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced two agreements in a new therapeutic area for the Company, post-traumatic stress disorder.  Most recently, a research agreement was entered into

Cambridge Cognition Holdings

Cambridge Cognition directors buy shares in company

Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, announced today that it was informed on the 21st July 2022 of the following purchases of the Company’s ordinary shares by Directors and PDMRs of the

No more posts to show